BiotechTube

Mavorixafor

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Oct 16, 2021 → Aug 27, 2024

NCT ID
NCT04154488

About Mavorixafor

Mavorixafor is a phase 1/2 stage product being developed by X4 Pharmaceuticals for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT04154488. Target conditions include Neutropenia.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT06858696Phase 1Recruiting
NCT04154488Phase 1/2Completed

Competing Products

20 competing products in Neutropenia

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaApproved
85
pegfilgrastimKyowa KirinPhase 2
52
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
77
caspofungin acetate + Comparator: AmBisomeMerckPhase 2
52
Imipenem + ImipenemMerckApproved
85
Posaconazole IV solution + Posaconazole powder for oral suspensionMerckPhase 1
33
Ceftolozane-Tazobactam + MeropenemMerckApproved
85
Ceftolozane-tazobactam IVMerckApproved
85
Daptomycin + DaptomycinMerckPhase 3
77
pegfilgrastimAmgenPhase 3
76
Neulasta (pegfilgrastim)AmgenApproved
84
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
84
Filgrastim Hospira (US) + US-approved Neupogen®PfizerPhase 1
32
HSP-130 + US-approved Neulasta + EU-approved NeulastaPfizerPhase 1
32
linezolid + vancomycinPfizerPhase 3
76
AnidulafunginPfizerPhase 1/2
40
Nivestim®PfizerPre-clinical
22
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
22
VoriconazolePfizerPhase 1/2
40
Filgrastim Hospira (US) + U.S.-approved Neupogen®PfizerPhase 1
32

Other Products from X4 Pharmaceuticals

Mavorixafor + PlaceboPhase 3
69
Mavorixafor + PlaceboPhase 3
69
X4P-001Phase 2
44
X4P-001 + NivolumabPhase 1/2
33
X4P-001 + axitinibPhase 1/2
33